Form 4: Third Rock Ventures Sells Shares of Tango Therapeutics (TNGX)

Third Rock Ventures IV, L.P. sold shares of Tango Therapeutics (TNGX) on July 22 and 23, 2024, reducing its holdings.

Summary

• Third Rock Ventures IV, L.P. sold 262,740 shares of Tango Therapeutics (TNGX) common stock on July 22, 2024, at a weighted average price of $9.7819 per share.
• The prices for the July 22nd sale ranged from $9.75 to $9.91.
• Following this transaction, Third Rock Ventures IV, L.P. directly held 18,197,074 shares.
• On July 23, 2024, Third Rock Ventures IV, L.P. sold an additional 125,000 shares at a weighted average price of $9.7868 per share, with prices ranging from $9.75 to $9.90.
• After the second sale, their direct holdings decreased to 18,072,074 shares.
• The reporting entities include Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC.
• Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a major shareholder is reducing its position, which could create selling pressure. However, it's a common practice for venture capital firms.

Negatives

• Third Rock Ventures, a major shareholder, is reducing its stake in Tango Therapeutics.

Risks

• Continued selling pressure from Third Rock Ventures could negatively impact the stock price of Tango Therapeutics.

Industry Context

Venture capital firms often distribute shares to their limited partners or reduce their holdings in portfolio companies as funds mature. This is a common practice and doesn't necessarily reflect a negative view of Tango Therapeutics' prospects.

Stakeholder Impact

• Shareholders may experience short-term price volatility due to the share sales.
• The company may need to manage potential concerns from investors regarding the reduced stake of a major shareholder.

Key Dates